Abstract
The “Specific Mechanism” as part of the accession of new Member States to the EC limits the free movement of goods between new and old Member States with respect to certain pharmaceuticals that could not find patent protection in the new Member States prior to accession. While the Specific Mechanism derogates from the principles of intra-Community free trade, it does not alter the rules of domestic patent law applicable in the respective Member States. As a consequence, the Specific Mechanism can only have an effect where domestic patent law gives the patentee the right to prevent parallel importation from other Member States or third countries. At least in the UK, this does not seem to be the case.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: IIC - International Review of Intellectual Property and Competition Law
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
